Genprex, Inc.
GNPX$8M
Micro CapNASDAQPharmaceutical Preparations🇺🇸North AmericaAUSTIN
Drugs in Pipeline
1
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
This month
Market Overview
Stock performance and key metrics
GNPX News
Catalyst Timeline
1 upcoming, 2 past
Phase 2Next
quaratusugene ozeplasmid Phase 2 Est. Readout
June 2026~Estimatedquaratusugene ozeplasmid62
Estimated primary completion for quaratusugene ozeplasmid trial (NCT05703971) in Small Cell Lung Cancer Extensive Stage. Topline data typically follows completion by weeks to months.
SourceDrug Pipeline
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
quaratusugene ozeplasmid | Phase 2 | Carcinoma, Non-Small Cell Lung | - | - |
Catalyst Verdict
Market-Implied Move
Regulatory Approvals
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply